----item----
version: 1
id: {87E0A64A-35CC-4F57-9C26-D83020918951}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/06/18/Pfizer finally begins Phase III for GlycoMimetics sickle cell drug
parent: {769D51CF-9365-4F63-B3B8-1BC4756B63D2}
name: Pfizer finally begins Phase III for GlycoMimetics sickle cell drug
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 857670be-f3e4-46ab-96bf-4ec0c13b3ace

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 194

{3B33748A-17E9-4241-8447-989BB3484DFB}|{38CC267C-7BFB-437D-BEA0-27DBA7B77873}|{3FA7743D-5DAB-49A3-B30D-DF5079ADB082}|{29C8E5B9-B01E-4DEE-A123-14D70756095B}|{B3122C5E-FF3F-438A-9C93-1B54DC1286A5}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 66

Pfizer finally begins Phase III for GlycoMimetics sickle cell drug
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 66

Pfizer finally begins Phase III for GlycoMimetics sickle cell drug
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1687

<p>GlycoMimetics will receive the final $20m of a $35m milestone payment from Pfizer now that the big pharma company has initiated a long-delayed Phase III clinical trial for rivipansel (GMI-1070) in the treatment of patients hospitalized for painful vaso-occlusive crises associated with sickle cell disease.</p><p>Gaithersburg, Maryland-based GlycoMimetics received the first $15m in <a href="http://www.scripintelligence.com/business/Pfizer-pays-15m-advance-on-PhIII-milestone-for-sickle-cell-drug-351938" target="_new">May 2014</a> even though the 350-patient Phase III trial's start date was unknown. The company then said in <a href="http://www.scripintelligence.com/business/Deal-Notes-GlycoMimeticsPfizer-PharmacyclicsServier-TG-TherapeuticsRhizen-TakedaBioMotiv-AmherstNovaDel-354172" target="_new">September</a> that Phase III would be delayed by a manufacturing development issue. </p><p>Pfizer told <i>Scrip</i> in <a href="http://www.scripintelligence.com/home/Pfizer-promotes-underappreciated-RandD-pipeline-356297" target="_new">January</a> that it planned to begin the late-stage study sometime this year after it resolved formulation issues for rivipansel. Pfizer agreed to take over Phase III development of the pan-selectin inhibitor under a <a href="http://www.scripintelligence.com/home/GlycoMimetics-makes-good-with-340m-sickle-cell-drug-deal-with-Pfizer-322326" target="_new">2011 deal</a> that is worth up to $340m in milestone fees plus royalties to GlycoMimetics.</p><p>The biotech company's stock jumped during the last few hours of trading on 23 June based on the Phase III study's initiation. GlycoMimetics closed up 12.1% at $8.79 per share.</p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 313

<p>GlycoMimetics will receive the final $20m of a $35m milestone payment from Pfizer now that the big pharma company has initiated a long-delayed Phase III clinical trial for rivipansel (GMI-1070) in the treatment of patients hospitalized for painful vaso-occlusive crises associated with sickle cell disease.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 66

Pfizer finally begins Phase III for GlycoMimetics sickle cell drug
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150618T150001
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150618T150001
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150618T150001
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029074
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 66

Pfizer finally begins Phase III for GlycoMimetics sickle cell drug
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

199200264
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{B322F30F-1522-4633-91A4-A2EF3216848C}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359019
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042412Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

857670be-f3e4-46ab-96bf-4ec0c13b3ace
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042412Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
